AMAG Pharmaceuticals (AMAG) Downgraded by JPMorgan Chase & Co.

Share on StockTwits

JPMorgan Chase & Co. lowered shares of AMAG Pharmaceuticals (NASDAQ:AMAG) from a neutral rating to an underweight rating in a research note released on Tuesday, MarketBeat reports. They currently have $18.00 price objective on the specialty pharmaceutical company’s stock, down from their prior price objective of $20.00.

Several other equities research analysts have also recently issued reports on the company. BidaskClub cut AMAG Pharmaceuticals from a hold rating to a sell rating in a research note on Tuesday. Cantor Fitzgerald set a $18.00 price target on AMAG Pharmaceuticals and gave the company a hold rating in a research note on Friday, November 2nd. Cowen set a $19.00 price target on AMAG Pharmaceuticals and gave the company a hold rating in a research note on Thursday, November 1st. Zacks Investment Research cut AMAG Pharmaceuticals from a hold rating to a strong sell rating in a research note on Friday, October 5th. Finally, ValuEngine upgraded AMAG Pharmaceuticals from a buy rating to a strong-buy rating in a research note on Wednesday, October 3rd. Three research analysts have rated the stock with a sell rating, seven have issued a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of Hold and an average target price of $21.97.

Shares of AMAG stock traded down $0.35 during trading on Tuesday, hitting $17.84. The company had a trading volume of 693,138 shares, compared to its average volume of 966,978. The company has a current ratio of 2.86, a quick ratio of 2.72 and a debt-to-equity ratio of 0.34. The stock has a market cap of $644.43 million, a P/E ratio of -3.12 and a beta of 0.23. AMAG Pharmaceuticals has a one year low of $11.95 and a one year high of $26.10.

AMAG Pharmaceuticals (NASDAQ:AMAG) last issued its quarterly earnings results on Thursday, November 1st. The specialty pharmaceutical company reported ($1.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.77) by ($1.11). The company had revenue of $122.20 million during the quarter, compared to the consensus estimate of $118.23 million. AMAG Pharmaceuticals had a negative net margin of 6.98% and a negative return on equity of 13.65%. The company’s quarterly revenue was down 1.7% on a year-over-year basis. During the same quarter last year, the firm posted ($4.31) earnings per share. Analysts forecast that AMAG Pharmaceuticals will post -2.85 EPS for the current year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Advisors Asset Management Inc. lifted its stake in AMAG Pharmaceuticals by 791.6% during the second quarter. Advisors Asset Management Inc. now owns 58,970 shares of the specialty pharmaceutical company’s stock worth $123,000 after purchasing an additional 52,356 shares during the last quarter. Piedmont Investment Advisors LLC bought a new stake in AMAG Pharmaceuticals during the second quarter worth $156,000. Meeder Asset Management Inc. lifted its stake in AMAG Pharmaceuticals by 590.9% during the second quarter. Meeder Asset Management Inc. now owns 8,947 shares of the specialty pharmaceutical company’s stock worth $174,000 after purchasing an additional 7,652 shares during the last quarter. HighPoint Advisor Group LLC acquired a new position in shares of AMAG Pharmaceuticals during the third quarter worth $188,000. Finally, NumerixS Investment Technologies Inc increased its holdings in shares of AMAG Pharmaceuticals by 243.2% during the second quarter. NumerixS Investment Technologies Inc now owns 12,700 shares of the specialty pharmaceutical company’s stock worth $257,000 after buying an additional 9,000 shares in the last quarter.

About AMAG Pharmaceuticals

AMAG Pharmaceuticals, Inc, a biopharmaceutical company, manufactures, develops, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds.

Further Reading: Trading Strategy

Analyst Recommendations for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply